The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract of each article:
Volume 14, Issue 2
Editorial
| Editorial | |
| Yali Friedman |
Articles
| Export compliance for life sciences | |
| John Avellanet |
| A new approach to improve technology commercialisation in university medical schools | |
| Courtney Price, Richard Huston, Arlen D Meyers |
| Biotechnology business models work: Evidence from the pharmaceutical marketplace | |
| J Leslie Glick |
| Valuing biotechnology companies: Does classification by technology type help? | |
| Jacqueline Loh, Robert Brooks |
| Risk management for the biotechnology industry: A Canadian perspective | |
| Sandra Vanderbyl, Sherry Kobelak |
| Singapore’s biomedical sciences landscape | |
| Keat-Chuan Yeoh |
| Social responsibility for the use of genes, genomes and biotechnology in biotechnology companies: A commentary from the bioethical viewpoint | |
| Yoshihiro Okada, Kazuo N Watanabe |
Legal and Regulatory Updates
| Legal and regulatory update | |
| Gerry Kamstra, John Wilkinson |
Conference Report
| Maryland and Virginia unite at 2007 Mid-Atlantic Bio Conference | |
| Harley King |
Book Reviews
| Book Review: Stem cell wars: Inside stories from the Frontlines | |
| Grant H Skrepnek |
![[Facebook]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/facebook.png)
![[Google]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/google.png)
![[LinkedIn]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/linkedin.png)
![[Twitter]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/twitter.png)
![[Email]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/email.png)
{ 1 trackback }